All Updates

All Updates

icon
Filter
Partnerships
GoodRx partners with ARS Pharmaceuticals to offer discounted neffy nasal spray for allergic reactions
Health Benefits Platforms
Sep 26, 2024
This week:
M&A
N-able acquires Adlumin for USD 266 million to strengthen cybersecurity offerings
Next-gen Cybersecurity
Today
M&A
Bitsight acquires Cybersixgill for USD 115 million to enhance threat intelligence capabilities
Cyber Insurance
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Generative AI Infrastructure
Today
M&A
Snowflake acquires Datavolo to enhance data integration capabilities for undisclosed sum
Data Infrastructure & Analytics
Today
Product updates
Microsoft launches Copilot Actions for workplace automation
Foundation Models
Yesterday
M&A
Almanac acquires Gro Intelligence's IP assets for undisclosed sum
Smart Farming
Yesterday
Partnerships
Aduro Clean Technologies partners with Zeton to build hydrochemolytic pilot plant
Waste Recovery & Management Tech
Yesterday
Funding
Oishii raises USD 16 million in Series B funding from Resilience Reserve
Vertical Farming
Yesterday
Management news
GrowUp Farms appoints Mike Hedges as CEO
Vertical Farming
Yesterday
M&A
Rise Up acquires Yunoo and expands LMS monetization capabilities
EdTech: Corporate Learning
Yesterday
Health Benefits Platforms

Health Benefits Platforms

Sep 26, 2024

GoodRx partners with ARS Pharmaceuticals to offer discounted neffy nasal spray for allergic reactions

Partnerships

  • GoodRx, a prescription savings platform, partnered with ARS Pharmaceuticals to provide the lowest discounted cash price for neffy, a needle-free epinephrine nasal spray for type I allergic reactions.

  • Through this partnership, neffy will be available for USD 199 for a pack of two single-use devices at over 70,000 pharmacies nationwide, exclusively through GoodRx. This collaboration aims to enhance the accessibility and affordability of anaphylaxis treatment, offering a needle-free alternative to traditional auto-injectors for millions of Americans, especially children and adults who need to carry epinephrine.

  • neffy, recently approved by the FDA in August, is the first needle-free treatment for type I allergic reactions, including anaphylaxis, for adults and children weighing 30 kg (66 lbs) or more. This partnership aligns with GoodRx's mission to make essential medications more accessible and affordable while promoting healthcare innovation.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.